First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.

Jennifer R DiamondValentina Boni Emerson A LimGrzegorz NowakowskiRaul CordobaDaniel MorilloRay ValenciaIsabelle GenvresseClaudia MerzOliver BoixMelanie M FrigaultJoy M GreerAhmed M HamdyXin HuangRaquel IzumiHarvey WongVictor Moreno

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

VIP152 monotherapy, administered intravenously once weekly, demonstrated a favorable safety profile and evidence of clinical benefit in patients with advanced HGL and solid tumors.

Keyphrases

endothelial cells
open label
induced pluripotent stem cells
randomized controlled trial
combination therapy
pluripotent stem cells
cell death
signaling pathway